Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 20/20 | 0.59 |
| ▸ | HDAC3 | O15379 | 7/20 | 0.59 |
| ▸ | HDAC2 | Q92769 | 7/20 | 0.59 |
| ▸ | NCOR2 | Q9Y618 | 4/20 | 0.59 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.55 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.55 |
| ▸ | HDAC7 | Q8WUI4 | 4/20 | 0.55 |
| ▸ | HDAC10 | Q969S8 | 4/20 | 0.55 |
| ▸ | HDAC9 | Q9UKV0 | 4/20 | 0.55 |
| ▸ | HDAC5 | Q9UQL6 | 4/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | KDM1A | O60341 | 1/20 | 0.55 |
| ▸ | F3 | P13726 | 1/20 | 0.55 |
| ▸ | NAMPT | P43490 | 2/20 | 0.52 |
| ▸ | NCOR1 | O75376 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30006351 | 1.00 | HDAC1 (0.59) | HDAC1HDAC3HDAC2NCOR2HDAC11 | |
| Bromide SCHEMBL3943842 | 0.99 | HDAC1 (0.58) | HDAC1HDAC3HDAC2NCOR2HDAC11 | |
| Hydrochloric Acid SCHEMBL3943756 | 0.99 | HDAC1 (0.58) | HDAC1HDAC3HDAC2NCOR2HDAC11 | |
| Acetic Acid SCHEMBL4103112 | 0.97 | HDAC1 (0.59) | HDAC1HDAC3HDAC2NCOR2HDAC11 | |
| Phosphoric Acid SCHEMBL3948469 | 0.97 | HDAC1 (0.56) | HDAC1HDAC3HDAC2NCOR2HDAC11 | |
| SCHEMBL3940281 | 0.96 | HDAC1 (0.55) | HDAC1HDAC3HDAC2NCOR2HDAC11 | |
| Sulfuric Acid SCHEMBL3948204 | 0.96 | HDAC1 (0.55) | HDAC1HDAC3HDAC2NCOR2HDAC11 | |
| Succinic Acid SCHEMBL3948465 | 0.95 | HDAC1 (0.57) | HDAC1HDAC3HDAC2NCOR2HDAC11 | |
| Lactic Acid SCHEMBL3937225 | 0.94 | HDAC1 (0.56) | HDAC1HDAC3HDAC2NCOR2HDAC11 | |
| Fumaric Acid SCHEMBL3941169 | 0.94 | HDAC1 (0.56) | HDAC1HDAC3HDAC2NCOR2HDAC11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108883179-A | Histone deacetylase inhibitor is used to enhance the purposes of immunization therapy | 印第安纳大学研究与技术公司 | 2018-11-23 | — | — | CN | claimed |
| US-20250064925-A1 | METHOD OF TREATING CANCER USING A COMBINATION OF ENTINOSTAT AND AN ANTI-CSF-1R ANTIBODY | SYNDAX PHARMACEUTICALS, INC. | 2025-02-27 | — | — | US | disclosed |
| US-20240398944-A1 | COMBINATION OF HDAC INHIBITOR AND ANTI-PD-1 ANTIBODY FOR TREATMENT OF CANCER | SYNDAX PHARMACEUTICALS, INC. | 2024-12-05 | — | — | US | disclosed |
| CN-117881660-A | New forms of entinostat and maleic or succinic acid | 麦克法伦史密斯有限公司 | 2024-04-12 | — | — | CN | disclosed |
| CN-116893262-A | Patient Selection for Combination Therapy | 赛达克斯制药股份有限公司 | 2023-10-17 | — | — | CN | disclosed |
| CN-108139403-B | Patient selection for combination therapy | 赛达克斯制药股份有限公司 | 2023-05-09 | — | — | CN | disclosed |
| CN-114053284-A | Methods of treating breast cancer | 辛达克斯制药股份有限公司 | 2022-02-18 | — | — | CN | disclosed |
| CN-112513636-A | Selection of patients for combination therapy | 赛达克斯制药股份有限公司 | 2021-03-16 | — | — | CN | disclosed |
| CN-111278459-A | Combination therapy | 赛达克斯制药股份有限公司 | 2020-06-12 | — | — | CN | disclosed |
| CN-110944978-A | Compound containing entinostat, compound crystal form thereof, preparation method and pharmaceutical composition | 杭州领业医药科技有限公司 | 2020-03-31 | — | — | CN | disclosed |
| CN-110446504-A | With the antibody combined epigenetic modulators for treatment cancer of brain signal protein-4 D | VACCINEX INC | 2019-11-12 | — | — | CN | disclosed |
| CN-108883179-A | Histone deacetylase inhibitor is used to enhance the purposes of immunization therapy | 印第安纳大学研究与技术公司 | 2018-11-23 | — | — | CN | disclosed |
| CN-108430472-A | Combination for the hdac inhibitor and anti-PD-L1 antibody for the treatment of oophoroma | 赛达克斯制药股份有限公司 | 2018-08-21 | — | — | CN | disclosed |
| US-RE45499-E1 | N-(2-aminophenyl)-4-[N-(pyridine-3-yl)-methoxycarbonyl-aminomethyl]-benzamide (MS-275) polymorph B | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-04-28 | — | — | US | disclosed |
| EP-2350005-B1 | N-(2-AMINOPHENYL)-4-[N-(PYRIDINE-3-YL)-METHOXYCARBONYL-AMINOMETHYL]-BENZAMIDE (MS-275)POLYMORPH B | Bayer Pharma AG (DE) | 2011-12-21 | — | — | EP | disclosed |
| EP-2350005-A1 | N-(2-AMINOPHENYL)-4-[N-(PYRIDINE-3-YL)-METHOXYCARBONYL-AMINOMETHYL]-BENZAMIDE (MS-275)POLYMORPH B | Bayer Schering Pharma Aktiengesellschaft (DE) | 2011-08-03 | — | — | EP | disclosed |
| US-7973166-B2 | N-(2-aminophenyl)-4-[N-(pyridine-3-yl)-methoxycarbonyl-aminomethyl]-benzamide (MS-275) polymorph B | BAYER SCHERING PHARMA AG (DE) | 2011-07-05 | — | — | US | disclosed |
| WO-2010022988-A1 | N-(2-AMINOPHENYL)-4-[N-(PYRIDINE-3-YL)-METHOXYCARBONYL-AMINOMETHYL]-BENZAMIDE (MS-275)POLYMORPH B | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-03-04 | — | — | WO | disclosed |
| US-20100056585-A1 | N-(2-Aminophenyl)-4-[N-(Pyridine-3-yl)-Methoxycarbonyl-Aminomethyl]-Benzamide (MS-275) Polymorph B | BAYER SCHERING PHARMA AG (DE) | 2010-03-04 | — | — | US | disclosed |
| US-20050215601-A1 | Therapeutic agent for rheumatic disease comprising benzamide derivative as active ingredient | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2005-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215601-A1 | Therapeutic agent for rheumatic disease comprising benzamide derivative as active ingredient | SSB, HRH2, TYR | HDAC1 13/4885HDAC3 88/4885HDAC2 17/4885 |
| US-20240398944-A1 | COMBINATION OF HDAC INHIBITOR AND ANTI-PD-1 ANTIBODY FOR TREATMENT OF CANCER | HDAC1, HDAC4, HDAC9 | HDAC1 1/4885HDAC3 9/4885HDAC2 6/4885 |
| US-20100056585-A1 | N-(2-Aminophenyl)-4-[N-(Pyridine-3-yl)-Methoxycarbonyl-Aminomethyl]-Benzamide (MS-275) Polymorph B | CYP3A5, MRPS35, NNMT | HDAC1 482/4885HDAC3 1186/4885HDAC2 767/4885 |
| US-20250064925-A1 | METHOD OF TREATING CANCER USING A COMBINATION OF ENTINOSTAT AND AN ANTI-CSF-1R ANTIBODY | CSF3R, CSF1R, HDAC1 | HDAC1 3/4885HDAC3 12/4885HDAC2 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.